Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No More Secrets: CDRH Post-Approval Study Web Site Goes Live April 6

This article was originally published in The Gray Sheet

Executive Summary

A public Web site tracking device companies' progress on FDA-required post-approval studies is scheduled to go live April 6

You may also be interested in...



FDA Expects Draft Document On Post-Approval Study Design By September

FDA hopes to complete a draft scientific document on how to design post-approval studies for medical devices by September, according to Danica Marinac-Dabic, director of the Division of Epidemiology within CDRH's Office of Surveillance and Biometrics

FDA Expects Draft Document On Post-Approval Study Design By September

FDA hopes to complete a draft scientific document on how to design post-approval studies for medical devices by September, according to Danica Marinac-Dabic, director of the Division of Epidemiology within CDRH's Office of Surveillance and Biometrics

HHS OIG Work Plan: FDA Oversight And DME, Inpatient Payments Make List

The Department of Health and Human Services Office of Inspector General 1outlined Oct. 1 more than 300 new and ongoing investigations on its to-do list for fiscal year 2009, including digging into how Medicare pays for durable medical equipment and examinations of hospital inpatient payments and FDA device oversight

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel